The Asia-Pacific contrast enhanced ultrasound market is evaluated to progress with a CAGR of 5.54% during the forecasting period of 2022 to 2030, capturing a revenue share of $662.04 million by 2030.

The rapid improvement in healthcare expenditure, especially in emerging nations such as China and India, in addition to the lack of well-organized reimbursement policies that propel the demand for cost-effective procedures, are among the key factors influencing the growth of the region’s market. However, the Asia-Pacific contrast enhanced ultrasound market will likely be hindered by factors such as the challenging acquisition of skilled labor in remote regions.

To know more about this report, request a free sample copy

The Asia-Pacific contrast enhanced ultrasound market growth assessment covers the study of China, Japan, Singapore, Taiwan, Australia & New Zealand, India, South Korea, Indonesia, and Rest of Asia Pacific. The growth of the contrast enhanced ultrasound market in China is mainly attributable to shifting demographics and disease trends as well as the development of the private healthcare sector. Moreover, owing to the influx of foreign investments in the Chinese healthcare industry, numerous private hospitals are being established in the country every year. The COVID-19 pandemic has also emphasized the need for incorporating contrast enhanced ultrasound technology in point-of-care diagnostics. In addition, the rising geriatric population plays a pivotal role in fueling the demand for contrast enhanced ultrasound as the elderly are more susceptible to cardiovascular and digestive ailments.

Conversely, the majority of hospitals in Japan are equipped with modern and cutting-edge ultrasound devices. Aligning with this, the adoption of contrast enhanced ultrasonography is accelerating in the country due to supportive regulations for innovative technology as well as high healthcare costs. Since the use of contrast enhanced ultrasound technology has significantly increased in primary care facilities and clinics over recent years, this factor is expected to further fuel the market growth in the Asia-Pacific during the forecast period.

The Asia-Pacific contrast enhanced ultrasound market is segmented into product, type, and end-user. The end-user segment includes hospitals, clinics, and ambulatory diagnostic centers. The hospital segment has a greater share within the contrast enhanced ultrasound market on account of the presence of a large patient pool and an installed advanced ultrasound equipment base. Furthermore, the availability of technicians and doctors with advanced expertise in utilizing machinery and contrast agents is also predicted to support the segment’s expansion.

On the other hand, the adoption rate of ultrasound scanners in clinics and other community-level clinics has increased, owing to the rise in the knowledge of cost-saving measures for early disease identification. Moreover, ultrasounds are also effective diagnostic techniques for urology, cancer, and cardiac care. Hence, on account of the increasing use of ultrasound in these specialties, urology, cardiology, and oncology clinics are set to be prospective markets for contrast agents.

Major enterprises operating in the Asia-Pacific contrast enhanced ultrasound market include Trivitron Healthcare Pvt Ltd, Koninklijke Philips NV, etc.

Trivitron Healthcare Pvt Ltd, headquartered in India, is a medical technology company that offers solutions to healthcare providers. The company’s products include newborn screening, radiography and C-arm systems, mammography, contrast media, ultrasound, breast biopsy system, radiation protection, bone densitometer, renal care, ventilators, and others.

Iopamiro® is a US FDA-approved X-ray contrast agent for the diagnosis of radiological procedures in radiology, CT, HSG, urography, and others.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.